Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Sunil Krishnan Krishnan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1340-4771; OpenAlex author ID A5026913056, A5108505915, A5132857145; NIH RePORTER profile ID 8547492. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 1, last author 7)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
1
Collaborators
82
Papers, trials and grants by year

2008: 1 trial · 2009: 1 trial · 2010: none · 2011: 1 paper, 1 grant · 2012: none · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 3 papers, 1 grant · 2021: 1 grant · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper, 1 grant

Papers 26

  1. Anti-EGFR liposomal drug delivery system loaded with AGY2 potentiates the anti-cancer effect of AGY2 against EGFR expressed pancreatic cancer. Co-author DOI 10.1016/j.ijpx.2026.100544↗
  2. Intratumoral Biosynthesis of Gold Nanoclusters by Pancreatic Cancer to Overcome Delivery Barriers to Radiosensitization. Co-author DOI 10.1021/acsnano.3c04260↗
  3. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Last author DOI 10.1016/j.ijrobp.2022.06.089↗
  4. Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer. Co-author DOI 10.3390/cancers14246137↗
  5. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. Co-author DOI 10.1016/j.jddst.2019.101374↗
  6. Visible-Light-Activated Molecular Nanomachines Kill Pancreatic Cancer Cells. Co-author DOI 10.1021/acsami.9b21497↗
  7. Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer: A Review. First author DOI 10.1097/mpa.0000000000001566↗
  8. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation. Last author DOI 10.1158/1535-7163.mct-18-0708↗
  9. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  10. miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers11070900↗
  11. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  12. Recent advances in radiation therapy of pancreatic cancer. Last author DOI 10.12688/f1000research.16272.1↗
  13. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  14. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Last author DOI 10.1016/j.ijrobp.2016.10.046↗
  15. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0171985↗
  16. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.30117↗
  17. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  18. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolida… Co-author DOI 10.1016/j.ijrobp.2015.12.003↗
  19. Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Last author DOI 10.1016/j.semradonc.2016.05.002↗
  20. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Last author DOI 10.1371/journal.pone.0156910↗
  21. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Last author DOI 10.3109/0284186x.2014.1000466↗
  22. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1111/hpb.12154↗
  23. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Co-author DOI 10.2217/nnm.13.84↗
  24. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2012.09.035↗
  25. Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them? Co-author DOI 10.3978/j.issn.2078-6891.2013.027↗
  26. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correl… Co-author DOI 10.1200/jco.2010.33.8038↗

Trials 2

  1. Vorinostat Plus Radiation Therapy in Pancreatic Cancer Principal investigator NCT00831493↗
  2. Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer Principal investigator NCT00614653↗

Grants 4

  1. In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy R01CA274415↗
  2. Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches U01CA216468↗
  3. In situ cancer cell specific synthesis of gold nanoclusters for radiosensitization of pancreatic cancer R21CA252156↗
  4. Integrated Imaging and Photothermal Ablation of Pancreatic Cancer Resection Margi R21CA133691↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Konstantin V Sokolov · 1 shared paper, 2 shared grants, 2020–2026 · strength 1.72
  2. Sang Hyun Cho · 1 shared grant, 2026 · strength 1.00
  3. Robert A. Wolff · 13 shared papers, 2011–2022 · strength 0.68
  4. Gauri Rajani Varadhachary · 13 shared papers, 2011–2022 · strength 0.68
  5. Matthew H. G. Katz · 12 shared papers, 2014–2022 · strength 0.65
  6. Christopher H. Crane · 13 shared papers, 2011–2022 · strength 0.65
  7. Jason B. Fleming · 12 shared papers, 2011–2019 · strength 0.57
  8. Steven Hsesheng Lin · 1 shared grant, 2021 · strength 0.56
  9. Milind M. Javle · 10 shared papers, 2011–2022 · strength 0.52
  10. Jeffrey E. Lee · 9 shared papers, 2011–2022 · strength 0.49
  11. Huamin Wang · 8 shared papers, 2014–2022 · strength 0.47
  12. Edward Agyare · 2 shared papers, 2020–2026 · strength 0.44
  13. Eugene Jon Koay · 6 shared papers, 2016–2022 · strength 0.37
  14. Saunjoo Yoon · 1 shared paper, 2026 · strength 0.32
  15. Joy C. Okoro · 1 shared paper, 2026 · strength 0.32
  16. Raviteja Bulusu · 1 shared paper, 2026 · strength 0.32
  17. Esther Frimpong · 1 shared paper, 2026 · strength 0.32
  18. Michael James Overman · 5 shared papers, 2016–2022 · strength 0.30
  19. Anirban Maitra · 5 shared papers, 2016–2019 · strength 0.28
  20. Eric Peter Tamm · 4 shared papers, 2017–2022 · strength 0.28
  21. Priya Bhosale · 4 shared papers, 2017–2022 · strength 0.28
  22. Awalpreet Singh Chadha · 5 shared papers, 2015–2017 · strength 0.26
  23. Aaron S. Schwartz‐Duval · 1 shared paper, 2024 · strength 0.24
  24. Mohamed Zaid · 3 shared papers, 2018–2022 · strength 0.23
  25. Bhanu Prasad Venkatesulu · 2 shared papers, 2018–2019 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.